Natera Says Signatera Showed 100% Sensitivity, 97% Specificity For Rectal Cancer Recurrence In Data Presented At ASTRO 2026
Share
Why It Matters
Natera's cancer blood test found nearly all rectal cancer returns. When a company shows strong test results, watch if doctors start using it more.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.